Intelligent discussion on HIV vaccine serves as a small consolation for slow progress: Bicentennial Symposium

Despite great public interest and desperate need, progress toward a viable human immunodeficiency virus (HIV) vaccine remains incredibly slow. Since Merck began its HIV vaccine research in 1985, the pharmaceutical company has yet to produce a vaccine capable of passing Phase II testing. Merck Labora...

Descripción completa

Detalles Bibliográficos
Autor principal: Reed, Harrison
Formato: Online Artículo Texto
Lenguaje:English
Publicado: YJBM 2011
Materias:
Focus: Yale School of Medicine Bicentennial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3117411/
https://www.ncbi.nlm.nih.gov/pubmed/21698049

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3117411/
https://www.ncbi.nlm.nih.gov/pubmed/21698049

Ejemplares similares